Annovis Bio, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ANVS, updated each market day.
ANVS AI Sentiment
AI sees no strong directional signal for Annovis Bio, Inc. stock over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Sector
Exchange
Market Cap
$46,946,964
Cap Tier
Employees
7
Headquarters
MALVERN, PA
Listed Since
Jan. 29, 2020
Website
ANVS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANVS Volatility
Annovis Bio, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
